the CALR gene have been discovered in 50–80% of ET or PMF patients without mutations of the JAK2 or MPL genes,5,6 indicating that this discovery is a further important step in the improvement of the diagnostic and characterisation of MPNs and for the application of kinase inhibitor therapy....
Indeed, various therapeutic agents, including specific cytotoxicants (e.g., anthracyclines, oxaliplatin), radiation therapy, and oncolytic viruses that induce immunogenic cell death (ICD) as well as CALR presentation along with ISR, stimulate the phagocytic uptake of tumor antigens by DCs, setting ...
Majeti R (2011) Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells. Oncogene 30:1009–1019 Article CAS Google Scholar Pietsch EC, Dong J, Cardoso R, Zhang X, Chin D, Hawkins R et al (2017) Anti-leukemic activity and tolerability of anti-human CD47 monocl...
Transduced K562 cells were subsequently purified by means of immunomagnetic selection (EasySep “Do-It-Yourself” Selection Kit; STEMCELL TECHNOLOGIES) using the anti-human p75-NGFR mouse monoclonal antibody (BD BIOSCIENCES). Purity of the NGFR+ cell fraction was assessed by flow cytometry after ...
(Nanjing,China).Primerl:5’.ATCTCGAGATGCTCCTTTCGGTGCCGCT.3’.Primer2:5’一CCAAGCCAAGG-ATGAGCTGTAGAAGCTT.3’.Anti.CRTmousemonoclonalantibodyWaSpurchasedfromCST(Boston,USA).Anti.CD68mousemonoclonalantibodywasobtainedfromAbeam(Cambridge,UK);pactinwasacquiredfromProteintechgroup(Chicago,USA);pKH26was...
MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med 2014; 20: 460–469. 6. Pernot S, Terme M, Voron T, Colussi O, Marcheteau E, Tartour E et al. Colorectal cancer and immunity: what we know and perspectives. World J Gastroenterol 2014; 20: 3738–3750. 7. ...
Importantly, TLR4 mutations also affect the propensity of breast cancer patients to relapse after immuno- genic anti-cancer therapy (with anthracyclines or localized radiotherapy), thus providing the first molecular epidemiolo- gical evidence that the immune system actually contributes to the efficacy ...
While there is promise for improvement in vision with intravitreal anti-VEGF agents, there are also shortcomings in terms of variable response to therapy as well as loss of efficacy in a subgroup of patients. Over the years, many endogenous inhibitors of angiogenesis including various anti-...